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The risk for the development of germ cell tumors is an im-
portant factor todealwith in themanagement of patientswith
disorders of sex development (DSD). However, this risk is
oftenhard to predict. Recently,major progress has beenmade
in identifying gene-products related to germ cell tumor de-
velopment (testis-specific protein-Y encoded and octamer
binding transcription factor 3/4) and in recognizing early
changes of germ cells (maturation delay, preneoplastic le-
sions, and in situ neoplasia). The newly recognized “undiffer-
entiated gonadal tissue” has been identified as a gonadal dif-
ferentiation pattern bearing a high risk for the development
of gonadoblastoma. It is expected that the combination of
these findings will allow for estimation of the risk for tumor
development in the individual patient (high risk/intermediate
risk/low risk). This article reviews the recent literature re-
garding the prevalence of germ cell tumors in patients with
DSD. Some major limitations regarding this topic, including
a confusing terminology referring to the different forms of
intersex disorders and unclear criteria for the diagnosis of
malignant germ cells at an early age (maturation delay vs.
early steps in malignant transformation) are discussed.
Thereafter, an overviewof the recent advances that havebeen
made in our knowledge of germ cell tumor development and
the correct diagnosis of early neoplastic lesions in this patient
population is provided. A new classification system for pa-
tients with DSD is proposed as a tool to refine our insight in
the prevalence of germ cell tumors in specific diagnostic
groups. (Endocrine Reviews 27: 468–484, 2006)
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I. Introduction
DISORDERSOF SEX development (DSD) or intersex dis-orders refer to conditions of incomplete or disordered
genital or gonadal development leading to a discordance
between genetic sex, gonadal sex, and phenotypic sex (1).
Together, DSD form a complex entity of heterogeneous eti-
ology that affect the four different dimensions (genetic sex,
gonadal sex, phenotypic sex, and behavioral sex) of sex de-
velopment. Many classification systems have attempted to
offer a comprehensive overview (1, 2). From a clinical as well
as a pathological point of view, the distinction between dis-
orders of gonadal dysgenesis (GD), which affect the level of
gonadal sex on the one hand, and syndromes of hypervir-
ilization and undervirilization, which affect the level of phe-
notypic sex on the other, seems to be the most valuable and
will therefore be used for the purpose of this article.
Since the rejection of the classic anthropocentric paradigm
for the treatment of patients with DSD as it was established
byMoney and Ehrhardt in the 1950s to 1970s (3), the optimal
management for these patients has been a continuous matter
of debate (4–15). However, the malignant potential of the
dysgenetic gonad (16–22) opposes itself firmly to the recent
interest in a more conservative approach regarding gonad-
ectomy. Safe guidelines for a policy of including patients in
a “watchful waiting” protocol are highly needed. They must
be evidence-based but can also profit from new, promising
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techniques for the diagnosis of in situ neoplastic lesions and
even preneoplastic changes of germ cells in gonadal biopsy
samples of intersex patients. Therefore, this article provides
a detailed and updated overview of the literature regarding
the occurrence of germ cell tumors in patients with DSD and
outlines the major recent progress that has been made in our
understanding of the pathogenesis of germ cell tumors and
the early recognition of (pre-)neoplastic changes. Based on
this broadened knowledge, a tentative new classification for
patients with DSD is proposed that may serve as a tool for
estimating the risk for germ cell tumor development in an
individual patient.
II. Gonadal Tumors in Intersex Patients
The so-called “type II germ cell tumors of the testis and the
dysgenetic gonad” (Table 1) (for a detailed overview of the
various types of germ cell tumors and their characteristics, see
Ref. 23) are by far the most frequently occurring and feared
tumors in patients with DSD. Therefore, this review will ex-
clusively focus on this groupof tumors.However, sporadically,
other gonadal (benign and malignant) neoplasms are reported
in patients with DSD, often in combination with the above-
mentioned type II germ cell tumors. These include sex cord
(SC)-stromal tumors [juvenile granulosa cell tumor (24), Sertoli-
Leydig cell tumor (25), and Sertoli cell nodules (26–28)] and
epithelial tumors [Brenner tumor (29), mucinous cystadenoma
(24, 29), and Mu¨llerian cyst (26)].
The invasive type II germ cell tumors that are encountered
in the intersex gonad are the seminoma (if the gonad is
considered a testis)/dysgerminoma (DG) (if the gonad is
considered an ovary) and the nonseminoma. The develop-
ment of these invasive tumors is always preceded by the
presence of an in situ neoplastic lesion—intratubular germ
cell neoplasia unclassified (ITGNU) or gonadoblastoma (GB)
(for a detailed histological description of ITGNU, GB, and
invasive tumors, see Ref. 30). The ITGNU lesion is commonly
known as carcinoma in situ (CIS), and although this latter
term, suggesting a neoplasm of epithelial origin, is less ac-
curate, we will use it for the purpose of this review.
Germ cells in intersex gonads may undergo transient be-
nign changes, pointing at a delay in their maturation, which
are often hard to distinguish from an in situ neoplastic lesion
(28, 31). However, this benign condition may, in some cases,
predispose to malignancy (see Section V). Because gonadec-
tomies in patients with DSD are often performed prophy-
lactically in early childhood, most of the encountered
changes in germ cells are benign or in situmalignant lesions.
Although -human chorionic gonadotropin (choriocarci-
noma) and 1-fetoprotein (yolk sac tumor) are well-estab-
lished serum tumor markers for the diagnosis and follow-up
of specific type II germ cell tumors (32–34), no studies exist
at present on the value and applicability of these and other
serum markers [placental-like alkaline phosphatase (PLAP),
octamer binding transcription factor 3/4 (OCT3/4), testis-
specific protein-Y encoded (TSPY)] for screening and early
tumor detection in patients with DSD.
III. The Prevalence of Germ Cell Tumors in Patients
with Disorders of Sex Development
The prevalence of germ cell tumors is increased in patients
with DSD containing Y chromosome material in their karyo-
type and is probably related to the presence of the TSPY gene
(see Section IV.B) (35–39). The presence of SRY or other sex
determining genes is irrelevant in this context. The ectopic
position of the (dysgenetic) testis adds to this risk because the
prevalence of germ cell tumors in simple cryptorchidism is
TABLE 1. The five types of germ cell tumors (based on Ref. 23)
Type Anatomical site Phenotype Age Originating cell Genomic imprinting Genotype
I Testis/ovary/sacral
region/retroperitoneum/
mediastinum/neck/midline
brain/other rare sites
(Immature)
teratoma/yolk-
sac tumor
Neonates and
children
Early PGC/
gonocyte
Biparental
partially erased
Diploid (teratoma),
Aneuploid (yolk-
sac tumor): gain
of 1q, 12(p13),
and 20q, loss of
1p, 4 and 6q
IIa Testis Seminoma/
nonseminoma
15 yr (median,
35 and 25 yr)
PGC/gonocyte Erased Aneuploid (/
triploid): gain of
X, 7, 8, 12p and
21, loss of Y, 1p,
11, 13 and 18
Ovary Dysgerminoma/
nonseminoma
4 yr PGC/gonocyte Erased Aneuploid
Dysgenetic gonad Dysgerminoma/
nonseminoma
Congenital PGC/gonocyte Erased Diploid/tetraploid
III Testis Spermatocytic
seminoma
50 yr Spermatogonium/
spermatocyte
Partially complete
paternal
Aneuploid: gain
of 9
IV Ovary Dermoid cyst Children/adults Oogonia/oocyte Partially complete
maternal
(Near) diploid,
diploid/tetraploid,
peritriploid (gain
of X, 7, 12 and
15)
V Placenta/uterus Hydatidiform mole Fertile period Empty ovum/
spermatozoa
Completely
paternal
Diploid (XX and
XY)
a Germ cell tumors occurring along the midline of the body (anterior mediastinum, midline of the brain) also belong to the group of type II
germ cell tumors.
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estimated at four to 10 times the normal prevalence of 6–11
per 100,000 (17, 30, 40, 41).
Traditionally, the prevalence of germ cell tumors in patients
with GD is estimated at around 30% (17) and in patients with
undervirilization syndromesat 5–10%(42, 43).However, reported
prevalencenumbersperdiagnostic groupmayvary considerably.
Inourview, this isat least inpartdue to twomajormethodological
problems. First, there are nowell-established criteria for the diag-
nosis of early neoplastic changes (CIS) in young children,
leading to a different interpretation of results by different
research groups (see below) (28, 44). Second, the terminology
and classification systems that are used at present are ex-
tremely confusing. Several synonyms and eponyms are used
in literature. A definition for the terminology used in an
individual article is often lacking. Moreover, the actual clas-
sification system is based on phenotypic, genetic, and patho-
logical criteria at the same time and shows several overlaps
(for an example of the actual classification of patients with
DSD and encountered synonyms in literature, see Table 2).
This situation evidently leads to inconsistent classification of
patients, which hampers a good insight in the prevalence of
malignancy in specific diagnostic groups.
In the following paragraphs, an estimation of the preva-
lence of germ cell tumors in intersex patients is made, based
on combined patient series from a review of the literature.
For this purpose, intersex patients were divided into three
major groups, based on a common underlying pathophysi-
ological mechanism per group.
TABLE 2. Example of a currently used classification of patients with DSD and encountered synonyms in literature adapted from
Grumbach MM et al. (2)
Syndrome Major group Subgroups Encountered synonyms
Female PHP Hypervirilized females
CAH
CYP19 aromatase deficiency
Exogenous androgens
Male PHP Hypovirilized males
End organ resistance for testosterone
action
CAIS Morris’ syndrome, testicular
feminization
PAIS Reifenstein’s syndrome
Disorders in testosterone and
dihydrotestosterone biosynthesis
StAR deficiency
3-HSDII deficiency
CYP17 deficiency
17-HSD3 deficiency
5-reductase II deficiency
Testicular unresponsiveness to LH
and hCG
Leydig cell hypoplasia/agenesis
Dysgenetic male PHPa ** Incomplete GDb, partial GDb, mixed
GDc **
XO/XY mosaicism*
Structurally abnormal Y, Xp,
9p,10q
Gene mutations (WT1, SOX9, SF1,
etc.)
WT1, Denys-Drash, Frasier, WAGR (if
WT1 deleted), SOX9: campomelic
dysplasia
Defects in synthesis, secretion, or
action of AMH
Persistent Müllerian duct syndrome
Exogenous estrogens/progestagens
GD
47,XXY Klinefelter’s syndrome
45,X Turner’s syndrome
45,X/46,XY and variants (/ Turner
stigmata)*
Turner’s syndrome (if Turner
stigmata)
Pure (complete) GDd complete 46,XY GD Swyer’s syndrome
complete 46,XX GD
True hermaphroditisme
Incomplete forms of GDb **
CAH, Congenital adrenal hyperplasia; PHP, pseudohermaphroditism; AMH, anti-Müllerian hormone; StAR, steroidogenic acute regulatory
protein; WT-1, Wilms’ tumor 1 gene; WAGR, Wilms’ tumor aniridia genitourinary anomalies and mental retardation; SOX9, SRY-box-related
gene 9; SF-1, steroidogenic factor 1; hCG, human chorionic gonadotropin. Asterisks represent categories showing partial overlap.
a (Mostly ambiguous) phenotype resulting from the presence of bilateral dysgenetic testes.
b (Mostly ambiguous) phenotype resulting from the presence of bilateral dysgenetic testes or one dysgenetic testis on one side and a streak
on the other side.
c (Mostly ambiguous) phenotype resulting from the presence of one dysgenetic testis on one side and a streak on the other side.
d Normal female phenotype (without Turner stigmata) in the presence of bilateral streak gonads (devoid of germ cells) in a 46,XX or 46,XY
individual.
e (Mostly ambiguous) phenotype resulting from the presence of both testicular tissue consisting of seminiferous tubules and ovarian tissue,
containing germ cells that are all enclosed in primordial and eventually growing follicles in the same individual, either in a single gonad or
in opposite gonads.
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A. Hypervirilization syndromes
These include 46,XX individuals who are exposed to an-
drogens (endogenous due to genetic defects in enzymes in-
volved in adrenal steroid hormone production or of exoge-
nous origin) during fetal life or thereafter (2). The diagnosis
is based on clinical and biochemical grounds and is usually
made at birth.
Patients with hypervirilization syndromes are not at risk
for the development of germ cell tumors. The gonadal tissue
always consists of well-differentiated ovaries, and the chro-
mosomal constitution is 46,XX.
B. Undervirilization syndromes
These are caused by errors in testosterone biosynthesis, by
testicular unresponsiveness to stimulation from the pitu-
itary, or by defects in androgen-dependent target tissues and
result in an ambiguous or female phenotype in a patient with
a 46,XY karyotype (2).
For patients with male pseudohermaphroditism (the un-
derlying defect not being further specified in the original
articles), combined series reveal a tumor prevalence of 2.3%
(3 of 129 patients) (19, 44–46).
The first reported prevalence of germ cell tumors in the
androgen insensitivity syndrome (AIS)was 22% (25). Later, this
was corrected to 5–10% (42, 43). In combinedmore recent series
of samples mostly obtained after prophylactic gonadectomy,
the calculated prevalence is 5.5% (15 of 270 patients) (19, 24,
26–28, 44, 45, 47–50). Although data are limited, the risk seems
to be markedly higher in the partial form (PAIS) [12 of 80
patients (15%)] (28, 48, 50) than in the complete variant (CAIS)
[1 of 120 patients (0.8%)] (19, 24, 28, 48–50). In our view, this
difference is explained by the fact that there is a rapid and total
loss of germ cells inCAIS, starting from the age of 1 yr,whereas
PAIS patients have maintained their germ cell population at
about two thirds of the normal number at puberty (28). How-
ever, in this context it is important to note that at present, none
of the existing in vivoor in vitro testsdistinguishunambiguously
between CAIS and PAIS (51–54).
Tumorprevalence inAISmarkedly increases after puberty and
reaches 33%at the age of 50 yr (19).However, no data exist on the
estimated prevalence in CAIS vs. PAIS patients at this age.
For other causes of undervirilization, series are too small to
draw conclusions: one tumor is reported in a series of six pa-
tients with 17-hydroxysteroid dehydrogenase (17-HSD) de-
ficiency (17%) (28), no tumors are found in a series of three
patients with 5-reductase deficiency (49) and of two patients
with Leydig cell hypoplasia (28).
With the exception of one case report of a GB, sufficiently
supported by published histological findings in a CAIS pa-
tient (55), all the reported tumors in the group of patients
with undervirilization syndromes are CIS lesions (81%) or
seminomas (19%).
The prevalence of preinvasive tumor lesions found in pro-
phylactic biopsy samples (usually performed at a very young
age) in PAIS patients (15%) is unexpectedly high compared
with the total group of undervirilized patients (2.3%).
Due to the widespread policy of prophylactic gonadec-
tomy, invasive tumors in these patients are rare at present,
but the hypothesis that all CIS lesions will finally result in an
invasive tumor (56) explains the higher prevalence in older
series. However, in our view, the real prevalence of CIS
lesions in gonadectomy samples of young children might be
lower than the calculated 5.5%, because the benign condition
of maturation delay can easily be misinterpreted as CIS and
may cause a significant bias in some of the reported series (48,
49, 57) (see Section V.B). The recent tendency to leave the
gonads in place, fixed in the scrotum in phenotypic males,
and to include them in strict follow-up protocols will allow
a better insight in the risk formalignant transformation of the
testis in undervirilized patients in the future.
C. Gonadal dysgenesis
Gonadal dysgenesis (GD) is defined as an incomplete or
defective formation of the gonads, as a result of a disturbed
process of migration of the germ cells and/or their correct
organization in the fetal gonadal ridge. Structural or numer-
ical anomalies of the sex chromosomes or mutations in genes
involved in the formation of the urogenital ridge and in sex
determination of the bipotential gonadmostly underlie these
disorders (2, 58–61).
A clear insight in the prevalence of germ cell tumors in
patients with GD is hampered by the existing confusion
regarding nomenclature, which is most pronounced for this
patient category (see Table 2).
Four series report on the prevalence of germ cell tumors
in GD (not further specified): A germ cell neoplasia is found
in 48 of 228 patients (21%) (18, 19, 44, 62). Most frequent are
isolated GBs [26 of 48 (54%)] and DGs [11 of 48 (23%)]. Five
(10%) consist of a combined GB and DG, two GB (4%) are
associated with a nonseminoma, one is a combined GB and
CIS lesion (2%), and three (6%) isolated CIS are reported.
In two series of patients with 46,XY GD, the tumor prev-
alence is 30–33% (17, 63). However, one series of 11 patients
with 46,XY dysgenetic male pseudohermaphroditism re-
ports CIS in 100% of cases (64). In our view, most of the germ
cell lesions described in this series reflect a state of matura-
tion delay of the germ cells (see Section V.B). Therefore, this
study will not be included in further calculations.
In series of patients with mixed GD, or asymmetrical go-
nadal differentiation, the overall prevalence of germ cell
tumors is 18 of 119 patients (15%) (19, 20, 24, 45, 46, 65), which
is considerably lower than the previously reported preva-
lence of 33% (19). The practice of performing an early pro-
phylactic gonadectomy probably explains at least in part this
difference. A total of 38.5% of the tumors are GB, 23% are
composed of GB and DG, 38.5% are isolated DG, and no CIS
lesions are found in these patient series. The findings cor-
respond to older studies (19).However, in contrastwith these
data, one study describes 13 patients with mixed GD in
which the prevalence of malignant lesions is 77% (10 of 13),
all of them beingCIS lesions, and 11 patientswith partial GD,
in which the tumor prevalence is 91% (10 of 11), all CIS, in
seven cases associated with GB (66). According to us, again,
the CIS lesions described here correspond to a state of mat-
uration delay of the germ cells (see Section V.B), and the data
will not be used for further calculations.
In selected series of patients with true hermaphroditism,
Cools et al. • Germ Cell Tumors in the Intersex Gonad Endocrine Reviews, August 2006, 27(5):468–484 471
 on September 5, 2006 edrv.endojournals.orgDownloaded from 
the prevalence of tumors is considerably lower. In three
studies, 426 patients are described (29, 44, 46). In these pa-
tients, 11 tumors occurred (2.6%), and the subtypes are two
of 11 (18%) GB, one of 11 (9%) CIS, six of 11 (55%) DG, and
two of 11 (18%) embryonal carcinoma (EC).
According to the older literature, germ cell tumors occur
in 15–20% of patients with proven mosaicism 45,X/46,XY
and variants. Recent data may suggest a higher prevalence:
independent series describe 17 patients in whom seven germ
cell tumors occur (41%) (63, 67, 68): four of seven tumors
(57%) are GB, one of seven (14%) is a GB associated with a
DG, and two of seven (28%) are DG. However, a bias due to
selective reporting of positive gonadectomy samples cannot
be excluded. In one series of four patients, CIS is found in all
cases (100%) (69), but again, the criteria used for the diagnosis
of what the authors call “an infantile CIS pattern” overlap
with the characteristics of germ cells delayed in their mat-
uration (see Section V.B). This study will not be used for
further calculations.
Molecular genetic techniques (mainly PCR) allow a more
reliable detection of a second (Y containing) cell line than
classic karyotyping. Therefore, some studies examine the
usefulness of routine PCR screening of all patients with
Turner syndrome for the presence of Y chromosome mate-
rial.We performed ameta-analysis of 11 studies dealingwith
this topic (70–80). It reveals that in 541 Turner syndrome
patients without Y chromosome material on cytogenetic
screening, 27 patients turned out to be mosaic for a Y-con-
taining cell line (5%). If a marker chromosome (mar) was
present in the original karyotype, the chance of detecting Y
chromosomal derivatives approximates 100%. A total of 557
patients were examined in these studies (in 16 patients Y
chromosome derivatives were already detected on cytoge-
netic screening). Thus, the total number of patients bearing
a Y chromosomal cell line was 43 of 557. In all of them, a
gonadectomy was performed, and GB was present in five of
them (11.6%). From these data it can be concluded that rou-
tine PCR examination of Turner syndrome patients to detect
high-risk individuals for the development of GB is not in-
dicated (the prevalence of GB in the total group being five of
557 or 0.9%). In contrast, if a marker chromosome is found
on cytogenetic karyotyping, the presence of Y chromosome
material (and an elevated risk for the development of GB)
must be suspected, and further examination by molecular
genetic techniques is warranted.
In a review of 15 cases of Frasier syndrome, the prevalence
of germ cell tumors is as high as 60% (88% GB, 12% DG) (81).
From these data, it is unclear whether this series reflects a
reliable estimation of the tumor risk in Frasier syndrome or
if an overrepresentation of positive cases has induced a se-
lection bias. In other syndromes caused by WT-1 mutations
(Denys-Drash, Wilms’ tumor aniridia genitourinary anom-
alies and mental retardation), the prevalence of germ cell
tumors may be equally high. Gonadal pathology is studied
in one series of 10 patients with Denys-Drash syndrome: GB
was found in two of five 46,XY patients (40%), whereas none
of the four 46,XX patients developed gonadal tumors (in one
additional patient without GB, the karyotype was not de-
termined) (82). No data are available concerning the prev-
alence of germ cell tumors in cases of GD due to mutations
in other newly discovered genes that are important for go-
nadal development (e.g., SF-1, SOX9, DAX1).
D. Conclusions
Combining of these data allows some important
conclusions:
1. The overall prevalence of germ cell tumors in the various
patient series with GD is estimated at 97 of 817 (12%).
2. In undervirilization syndromes, the overall prevalence
of germ cell tumors approximates 2.3%. However, because
this estimation is mainly based on prophylactically removed
gonadectomy samples, the prevalence in untreated patient
series is probably higher.
3. Within the group of undervirilization syndromes, germ
cell tumors are extremely rare in CAIS and more frequent
than expected in PAIS.
4. In contrast to patients with undervirilization syn-
dromes, germ cell tumors in patients with GD are frequently
found at a very young age [e.g., in the first year of life (20, 21,
62, 83)] or may even be present at birth (65).
5. CIS, arising in well-differentiated testicular tissue is
virtually the only precursor lesion found in patients with
undervirilization syndromes. In contrast, nearly all the in situ
neoplastic lesions in patients with GD are GBs, whether or
not (partially) overgrown by seminoma/DG [56 of 61 (92%)].
The CIS lesion accounts for only 8% (5 of 61) of precursor
lesions in patientswithGD and is probably only encountered
in the presence of testicular tissue (our personal
observations).
6. The presence of the Y chromosome (and of the TSPY
gene) was not an inclusion criteria in the largemajority of the
studies. Studies on patient series in which the presence of the
TSPY gene or protein in the gonadectomy samples or at least
in the patients’ karyotype is confirmed are highly needed to
get a better insight in the real malignant potential of the
dysgenetic gonad in selected series of high-risk patients.
7. The use of an unambiguous classification system of
clinical diagnoses and a clear definition of the used termi-
nology is indispensable for a correct interpretation of data
and for a better estimation of tumor risk in specific patient
series (e.g., 17-HSD deficiency, Leydig cell hypoplasia).
8. The routine search for mutations in genes involved in
gonadal differentiation (e.g., WT1, SF1, DAX1, SOX9) in
46,XY individuals with GD is essential to determine the tu-
mor risk in specific patient series.
A summary of the estimated tumor prevalences and the
type of precursor lesion is given in Table 3.
IV. The Use of Immunohistochemical Markers for the
Diagnosis of Germ Cell Tumors in Patients with
Disorders of Sex Development
The development of germ cell tumors in general is related
to events during fetal gonadogenesis, the malignant germ
cell being the neoplastic counterpart of a primordial germ cell
(PGC) or gonocyte (23). Therefore, immunohistochemical
markers that are expressed by normal PGCs can be used for
the diagnosis of malignant germ cell tumors. However, it is
important to note that none of these markers is able to dis-
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tinguish unambiguously between maturation delay of germ
cells (a benign condition, see Section V.A) and an in situ
neoplasm. Because such a discriminative marker is not to be
expected in the near future, additional criteria are indispens-
able to diagnose CIS in young children.
A set of relevant immunohistochemical markers (OCT3/4,
PLAP, c-KIT, TSPY, VASA) was specifically examined in
large series of gonads from intersex patients by our group
(for results and references, see Table 4). The markers
OCT3/4, c-KIT, and PLAP showoverlapping expression pat-
terns, but the use of the newer (both monoclonal and poly-
clonal forms of) OCT3/4 results in a well-circumscribed and
intense nuclear staining, is easiest for interpretation, and is
very robust, even if different methods of pretreatment and
tissue storage are applied (84). Therefore, it is largely pre-
ferred to the other two markers.
The in situ neoplastic lesions of the intersex gonad—GB
and CIS—are unambiguously characterized by a consistent
expression of OCT3/4 and an abundant expression of TSPY
(28, 62, 85). A careful analysis of the staining results sum-
marized in Table 4 reveals that they can only arise from
abnormal (developmentally delayed and/or dysgenetic) tes-
ticular tissue or from undifferentiated gonadal tissue (UGT)
(see Section VI), but not from normal testes or ovaries. The
possible roles of OCT3/4 and TSPY in the development of
germ cell tumors are discussed in Section IV.A and IV.B.
A. OCT3/4 (POU5F1)
OCT3/4 is consistently and specifically expressed in all
germ cell tumors with pluripotent potential and is therefore
used as a reliable marker for the diagnosis of CIS, GB, sem-
inoma/DG, and EC (84, 86). The diagnostic value of OCT3/4
has been confirmed in a series of independent studies (31,
87–92). The expression of the recently proposed immuno-
histochemical marker activator protein 2- (93) is similar to
OCT3/4 expression but offers no additional information.
The octamer binding transcription factor OCT3/4 is a
member of the family of POU (pit-1, oct-1, Caenorhabditis
elegans unc-86) transcription factors, genes that regulate the
expression of other target genes during mammalian devel-
opment (94). It is highly expressed during the earliest stages
of embryogenesis and in embryonic stem cells (ESC) (87, 95),
and is essential for the maintenance of pluripotency of these
cells. Up- or down-regulation of OCT3/4 in ESC as well as
in EC cell lines induces differentiation (95, 96). In the early
embryo, OCT3/4 is quickly repressed and soon becomes
exclusively confined to the germ cell lineage. However, loss
of OCT3/4 expression in PGCs does not lead to differenti-
ation of these cells but to apoptosis (97). Thus OCT3/4 is
required for the survival of PGCs. In female gonadal devel-
opment, OCT3/4 is expressed in oogonia and early oocytes,
but never in germ cells included in follicles (31, 98), and, in
accordance with this observation, it was suggested that
down-regulation of OCT3/4 is related to the entry of female
germ cells into meiosis (94). As a result, in the female gonad,
expression of OCT3/4 is high until 25wk gestational age, but
decreases sharply thereafter. At birth, hardly any positive
germ cell is detectable (98). In human male embryonic de-
velopment, OCT3/4 expression is confined to gonocytes,
which are positioned in the center of the tubule. During
gonadal development, gonocytesmigrate toward the periph-
ery, and once they make contact with the basal lamina (they
are now referred to as prespermatogonia), they lose OCT3/4
expression (in contrast to normal adult OCT3/4 expression
in murine spermatogonia; see Ref. 94). This results in a high
expression pattern of OCT3/4 early in the second trimester
and a constant decrease thereafter. In the perinatal period,
few tubules display a single, centrally located positive germ
TABLE 3. Summary of the estimated germ cell tumor prevalence in patients with DSD and type of precursor lesion
Estimated tumor prevalence
Type of precursor lesion
CIS GB
Undervirilization 2.3% (probably higher if untreated) 100% 0%
AIS 5.5% (20–30% if untreated)
CAIS 0.8%
PAIS 15%
GD 12% (probably 30% if untreated and/or selected
for the presence of the Y chromosome)
8% 92%
45,X/46,XY and variants 15–40%
46,XY GD 30%
Mixed GD/asymmetrical gonadal differentiation 15% (30% if untreated and/or selected for the
presence of the Y chromosome)
True hermaphroditism 2.6%
Frasier syndrome 60% (limited data)
Denys-Drash syndrome with 46,XY karyotype 40% (limited data)
TABLE 4. Immunohistochemical markers in germ cells and germ cell tumors
Testis .
Normal Delay Dysgenetic UGT Ovary CIS GB Seminoma Nonseminoma Refs
OCT3/4         EC 28, 62, 84–86, 92, 98–100, 120
PLAP         EC 28, 62, 98–100, 121
c-KIT        /  28, 62, 98–100, 122, 123
TSPY  2 2 2  2 2 /  28, 35, 62, 85, 99–101
VASA      / / /  28, 62, 98–100, 124
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cell (99, 100). Subsequently, it was shown that the expression
of OCT3/4 is abnormally prolonged in situations where
germ cells are delayed in their development (see Section V.A)
(28, 31, 62, 100).
In ESC-derived tumors in mice, the level of expression of
OCT3/4 was highly correlated with the formation and ag-
gressive properties of the tumors (absent or low levels of
OCT3/4 expression hampered tumor formation or resulted
in poorly aggressive, well-differentiated tumors, whereas
high levels of OCT3/4 led to frequent and highly aggressive
tumors, down-regulation of OCT3/4 in these tumors re-
sulted in their regression). Extrapolation of these data to the
noticed OCT3/4 expression in germ cell tumors led to the
suggestion that aberrant OCT3/4 expression might be of
pathogenetic relevance in the development of these tumors
and might determine their oncogenic potential (87).
B. The testis-specific protein-Y encoded (TSPY)
It was observed for many years that a GB almost exclu-
sively arises in the dysgenetic gonads of intersex patients
with a Y chromosome. Rare case reports of GB arising in
Y-negative patients date from an era before the use of mo-
lecular genetic techniques to exclude the presence of Y chro-
mosome material (16–19, 21). This led Page (39) in 1987 to
postulate the hypothesis that a gene on the Y chromosome
with a physiological function related to spermatogenesis in
normal males may act as an oncogene in the context of a
dysgenetic gonad. He referred to this hypothetical gene as
GBY (gonadoblastoma locus on the Y chromosome) (39). By
comparing the karyotypes of patients with GB and partially
deleted Y chromosome material, the GBY susceptibility re-
gion was further sublocalized to a small region on the short
arm (deletion interval 3E-3G and 4B) (38) or long arm (de-
letion interval 5E) of the Y chromosome (37), both close to the
Y centromere (Fig. 1). Themain candidate forGBY among the
seven known genes of the interval on Yp is TSPY, which also
has functional copies in the defined interval on Yq. In ac-
cordance with the original hypothesis of Page, the TSPY
protein is normally expressed in spermatogonia of the adult
male, and although its function is not fully understood, it is
thought to be related to their mitotic proliferation (36, 101).
Variations in the level of TSPY expression, resulting in fluc-
tuations in the staining intensity in immunohistochemical
experiments have been reported by different observers (28,
36, 62, 100, 101). In the fetal gonad, TSPY is expressed at a
constant level throughout pregnancy (99). However, TSPY
staining is more intense in fetal germ cells of trisomy 21
patients, which are delayed in their maturation (100), and
becomes abundant in germ cells of intersex patients (under-
virilization syndromes as well as GD) (28, 62). Furthermore,
the intensity of the TSPY staining is also abundant in CIS
(whether or not arising in intersex patients) (28, 101), GB (35,
62, 85), seminoma (35), and possibly in prostate cancer (102)
and hepatocellular carcinoma (103). Whether or not the ob-
served increase in staining intensity results from an up-
regulation of transcribed and translated TSPY copies has not
been examined so far.
From this section and Section IV.A, it can be hypothesized
that prolonged expression of OCT3/4 and increased expres-
sion of TSPY can provide the germ cells residing in an un-
favorable environment with additional tools to survive and
proliferate.
V. Maturation Delay vs. CIS: Transitional Changes of
the Germ Cells
A. Maturation delay of germ cells
According to the testicular dysgenesis syndrome hypoth-
esis that Skakkebaek and co-workers (104, 105) proposed,
germ cells that are not optimally nourished by Sertoli cells at
the time of fetal gonadogenesis undergo a delay in their
maturation, resulting in an increased risk for subfertility and
germ cell tumor formation. This model suggests that devel-
opmental delay of germ cells is the common underlying
mechanism in various apparently unrelated conditions, such
as exposure to xenoestrogens and antiandrogens (the so-
called “endocrine disruptors”) of the male fetus, certain con-
ditions caused by chromosomal aberrations (e.g., trisomy 21),
and DSD.
To test this hypothesis, we quantitatively and qualitatively
examined the expression of germ cell markers in male and
FIG. 1. Location of the TSPY gene on Yp. TSPY is located in the
pericentromeric region on Yp; homologous copies may be present on
Yq.
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female fetuses throughout pregnancy (98, 99) and compared
the expression patterns to those obtained in trisomy 21 fe-
tuses, undervirilization syndromes, and GD (28, 62, 100). We
found that in all these conditions, a subpopulation of germ
cells is indeed affected by maturation delay. In the testes of
males with trisomy 21 and of patients with undervirilization
syndromes andGD, the normalmigration of these early germ
cells toward the basal lamina and their subsequent differ-
entiation into prespermatogonia is disrupted. This becomes
apparent by their morphological similarity with the primi-
tive gonocyte, by their increased and prolonged expression
of the tumor markers OCT3/4, c-KIT, and PLAP, and by
increased intensity of immunohistochemical staining for
TSPY. The developmental delay present in the gonads of
male trisomy 21 patients, who have a moderately elevated
risk (estimated at 0.5%) for the development of germ cell
tumors is rather mild, whereas a more pronounced matu-
ration delay was demonstrated in the germ cells of patients
with undervirilization syndromes and especially in the tes-
ticular parts of gonads from patients with GD (28, 62, 100).
In UGT, characteristic for patients with GD and at high risk
for the development ofGB, germ cells, extremely retarded (or
blocked) in their maturation reside in a background of sup-
porting and stromal cells that failed themselves to differen-
tiate properly and to organize in structures characteristic for
normal male or female gonadal development (i.e., the for-
mation of testes or ovaries) (62).
Thus, our data confirm the model that a delay or block in
germ cell development is a common underlying mechanism
in various conditions such as trisomy 21 and DSD. To what
extent these data can be extrapolated to gonadal develop-
ment in male fetuses exposed to endocrine disruptors re-
mains to be examined at present.
B. Pitfalls in the diagnosis of early germ cell neoplasia
The prolonged expression of fetal germ cell markers/tu-
mor markers in the gonads of young patients with DSD has
led to a significant overdiagnosis of CIS in this patient pop-
ulation, because the mere presence of a tumor marker in a
germ cell with aberrant morphology (the morphology of a
CIS cell also closely resembles that of a primitive gonocyte)
was considered as a hallmark for its malignant transforma-
tion andwas thought to represent a “prepubertal CIS lesion”
(48, 49, 64, 66, 106). Therefore, we have proposed three ad-
ditional criteria—patient age, position of OCT3/4-positive
cells within the seminiferous tubule, and distribution of
OCT3/4-positive cells throughout the gonad—that allow
distinguishing between maturation delay and CIS in the
gonads of patients with undervirilization syndromes (28)
(Table 5). These criteria have recently been validated in an
independently performed study (107). The last two criteria
are also applicable on the dysgenetic testes of patients with
GD; however, the age criterion cannot be used in this pop-
ulation because the process of maturation delay is more
pronounced in this condition and was found up to the age
of 10 yr (our personal observations).
FIG. 2. Development of CIS in the testis of patients with
DSD. Germ cells that are delayed in their maturation are
characterized by prolonged OCT3/4 and increased TSPY
expression. Due to the unfavorable environment, most of
these germ cells will die, leading to tubular atrophy. How-
ever, surviving germ cells are prone to clonal expansion and
the formation of an in situ neoplasia.
TABLE 5. Additional criteria for the diagnosis of maturation delay and CIS in XY individuals with undervirilization syndromes
Maturation
delay Transition CIS
Patient age 1 yr Prepubertal 1 yr
Position of OCT3/4-positive cells within
the seminiferous tubule
Luminally Luminally and on the basal lamina On the basal lamina
Position of OCT3/4-positive cells
throughout the gonad
Widespread Confined to a specific region; rest of the
gonad is free of positive cells or
displays characteristics of maturation
delay
Confined to a specific region; rest of the
gonad is free of positive cells or
displays characteristics of maturation
delay
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C. Progression toward malignancy
From the previous sections, it can be concluded that mat-
uration delay of germ cells may indeed result in an increased
risk for neoplastic transformation, which is related to the
prolonged expression of OCT3/4 and increased TSPY ex-
pression, which provides the cell with equipment to survive
and proliferate. However, in most cases this is only a tran-
sient condition; despite their initial developmental delay,
immature germ cells lose OCT3/4 expression and differen-
tiate into a more mature cell type, or alternatively they die,
FIG. 3. Maturation delay vs. CIS in the testes of patients with undervirilization syndromes. A, Maturation delay: OCT3/4-positive tubules are
scattered throughout the gonad in a 6-month-old patient with 17-HSD deficiency. Note the central position of the OCT3/4-positive cells within the
tubules (OCT3/4staining;magnification,100).B,CIS:OCT3/4-positive tubules ina13-yr-oldPAISpatient.TheOCT3/4-positive tubulesare confined
to one limited area of the gonad, separated from the OCT3/4-negative areas by fibrous septa (OCT3/4 staining;100). C, Maturation delay: OCT3/4
(blue)-VASA (red) double staining (200) in a1-month-oldCAISpatient.OCT3/4-positive cells are located in the center of the tubule andare separated
from the basal lamina by at least one layer of Sertoli cells; VASA-positive cells, staining asmaturing germ cells, aremainly found on the basal lamina.
D, Preneoplastic lesion: OCT3/4 (blue)-VASA (red) double staining (200) in a 4-yr-old 17-HSD deficiency patient. OCT3/4-positive cells are found
centrally in the tubule and along the basal lamina. Normally maturing germ cells (characterized by the red VASA staining) are equally present in
the affected tubules. E, CIS: OCT3/4 (blue)-VASA (red) double staining (200) in a 13-yr-old PAIS patient. OCT3/4-positive cells are found almost
exclusively along the basal lamina. Affected tubules do not contain normally maturing germ cells anymore (characterized by the red VASA staining).
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due to the inappropriateness of their environment. However,
in the testes of patients with undervirilization syndromes
and GD, it was occasionally observed that OCT3/4-positive
PGCs/gonocytes manage to make contact with the basal
lamina and seem to definitively escape down-regulation of
OCT3/4 and further differentiation along the spermatogenic
pathway. These OCT3/4-positive and TSPY-positive germ
cells in contact with the basal lamina can now undergo mi-
totic proliferation and are prone to clonal expansion. On
immunohistochemical staining, this preneoplastic lesion is
characterized by the combined presence of OCT3/4-positive
and OCT3/4-negative germ cells on the basal lamina of the
seminiferous tubule. Luminally positioned OCT3/4-positive
cells may also be present (Table 5 and Figs. 2 and 3). This
pattern was hitherto seen only in prepubertal patients (28,
62). Thus, histologically, a continuum can be identified, from
maturation delay toward preneoplastic changes of the germ
cells and final organization into a typical CIS pattern.
Maturation arrest of tissue-determined stem cells has been
proposed previously as a common underlyingmechanism in
all epithelial-derived tumors as well as in tumors of hema-
topoietic origin (108). In this context, the recent observation
that global loss of genomic imprinting in mouse ESCs pre-
disposes these cells to malignancy by rendering them im-
mortal is of interest (109). Indeed, type II germ cell tumors
of the testis have been found to consistently show biallelic
expression of imprinted genes, i.e., they lack a somatic pat-
tern of genomic imprinting (110). Despite the fact that it
possibly concerns an intrinsic characteristic of the cell of
origin (a PGC/gonocyte), this loss of genomic imprinting
might in fact represent a step in the pathogenetic process of
malignant transformation. Extrapolation of these data to pa-
tients with DSD creates a model in which PGCs, insuffi-
ciently nourished by an inappropriate environment, undergo
a severe delay or arrest in their development, which is most
pronounced in those tissues with the lowest degree of dif-
ferentiation, thereby maintaining (or inducing) a status of
erased genomic imprinting and prolonged OCT3/4 expres-
sion of the germ cells (immortalization). Increased TSPY
expressionmay rapidly lead to expansive proliferation of this
immortal cell type (Fig. 4).
VI. CIS or Gonadoblastoma?
Why do some patients with DSD develop a CIS and others
a GB as an in situ neoplastic lesion? From Table 3 it becomes
apparent that CIS is the almost exclusive precursor lesion in
undervirilized patients, whereas GB is predominant in pa-
tients with GD. In the various undervirilization syndromes
and the (more frequently occurring) CIS lesion of the normal
adult male, it is clear that the gonadal tissue in which these
lesions originate always consists of well-differentiated tes-
ticular tissue. The detailed nature of the gonad inwhich a GB
can arise has been unclear so far. It was examined in some
patient series (16, 20, 64, 65, 67, 83). The combination of these
data reveals that the gonad of origin is considered as a dys-
genetic testis in 20% of cases and a streak in 26%, and that
it could not be determined in 54% of cases. Recently, we
hypothesized that GBs probably arise from surviving germ
cells residing in UGT and primitive SC (62), structures that
are only encountered in the context of GD and that remained
unrecognized so far.
The normal development of human fetal gonads is de-
scribed by Gondos (111) and is largely analogous to the
gonadal development and differentiation process analyzed
in detail inmice (112–114). At their arrival in the genital ridge
around the 5 wk gestational age, the germ cells and pre-
Sertoli/granulosa cells reside in the bipotential gonad with-
out specific organization. The first sign of sexual differenti-
ation, the formation of primitive SC, coincides with the
expression of SRY, aroundwk 6. Subsequent development of
the SC into seminiferous tubules depends on adequate gene
expression downstream of SRY. In the absence of SRY ex-
pression, no changes occur in the undifferentiated gonad
until the 12th wk, when the germ cells enter meiosis. It was
hypothesized that the UGT found in patients with GD rep-
resents this undifferentiated state of the gonad, where no
accurate SRY expression has taken place, but where, under
the influence of unknown male characteristics, meiosis and
progression along the default pathway are inhibited (Fig. 4).
Surviving PGCs in UGT and SC of the dysgenetic gonad
abundantly express TSPY, and a subpopulation of them also
expresses OCT3/4 (Table 4). We hypothesized that down-
FIG. 4. Overview of the pathogenetic mechanisms leading
to clonal expansion of germ cells in patients with DSD. The
original bipaternal pattern of genomic imprinting present
in the zygote has to be erased during PGC development to
install a uniparental pattern of maternal genomic imprint-
ing in the oocyte and paternal genomic imprinting in the
spermatozoa. Loss of genomic imprinting (or bialellic ex-
pression of imprinted genes, as is seen in the PGC/gonocyte)
may lead to immortalization. In DSD, due to the unsup-
portive environment, the normal maturation of germ cells
is interrupted. Maturation delay/arrest of the germ cells,
characterized by prolonged OCT3/4 expression (increased
survival of the PGC) and a maintained or induced status of
erased genomic imprinting, may lead to immortalization of
the cell. IncreasedTSPYexpressionmay cause proliferation
of this immortalized cell type.
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regulation of OCT3/4 in these PGCs results in apoptosis,
finally leading to the formation of a streak. However, the risk
of clonal expansion in these OCT3/4-positive, TSPY-positive
germ cells residing in UGT and SC is high and frequently
leads to the development of a GB (Figs. 5 and 6). If this
evolution takes place more rapidly than the progression to-
ward CIS, this would explain the more frequent finding of a
GB rather than a CIS lesion in dysgenetic gonads containing
FIG. 5. Model for the development of UGT, GB, and
CIS within the dysgenetic gonad. Top, In the devel-
oping embryo, germ cells migrate from the yolk sac
into the bipotential gonad and intermingle with pre-
Sertoli/granulosa cells. Middle, from right to left, In
the male, SRY expression in the sixth week after
conception induces organization of pre-Sertoli cells
and germ cells in primitive SC. Under the influence
of other male sex-determining genes downstream of
SRY, these SC differentiate into seminiferous tu-
bules. Pathological conditions can cause a block or
delay in the normal germ cell development, thereby
increasing the risk for CIS formation.Bottom, In GD,
inaccurate or absent SRY expression or a disturbed
expression of other male-determining genes prohib-
its SC formation or further differentiation of SC,
whereas progression along the meiosis-default path-
way is also blocked (bottom right). Surviving germ
cells residing in UGT (including immature SC) con-
tain a high risk for the development of GB (bottom,
middle).
FIG. 6. OCT3/4 and TSPY staining results in UGT and adjacent GB lesions. OCT3/4 (red)-TSPY (blue) double staining (magnification, 200)
in a 19-yr-old 46,XY patient with GD and bilateral GB. A subpopulation of germ cells (characterized by their positive TSPY staining) within
the UGT (A, left gonad; C, right gonad) adjacent to GB expresses OCT3/4. Most germ cells within the GB lesion express OCT3/4 and TSPY (B,
left gonad; D, right gonad).
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both SC or UGT and testicular tissue. Alternatively, it is
conceivable that immature germ cells, blocked in their mat-
uration but residing in SC or UGT, which is their natural
environment during early embryonic life, have increased
survival and proliferation chances compared with immature
germ cells residing in well-differentiated testicular tissue
(62). These findings are partially in line with a recently pub-
lished study (115) in which the authors state that GBs orig-
inate from germ cells developing along the female pathway
but failing to complete the meiotic prophase and to organize
in primordial follicles. However, in contrast to our data,
primitive SC, blocked in their further progression toward
seminiferous tubules, were not identified as containing a
high risk for the development of GB by these authors.
VII. Proposal for a New Classification of Patients
with Disorders of Sex Development according to
Their Risk for the Development of Germ Cell Tumors
(Fig. 7 and Table 6) and Future Perspectives
A review of the literature, as outlined in Section III, actually
reveals that a correct insight in the risk for germ cell tumor
development in patientswithDSD cannot be achieved for the
reasons stated in Section III. Therefore, we propose a new
classification for patients with DSD, based on the differen-
tiation type of the gonad, which is directly related to the risk
for tumor development (Fig. 7), and using a more homog-
enous terminology that avoids synonyms and overlapping
categories (Table 6). This classification system is partly in line
with the classification of patients with DSD as it was recently
proposed by the consensus conference on the management
of patients with DSD (Chicago, IL, October 2005), the results
of which are presented in Ref. 116. However, there are some
important modifications, and the classification system is ex-
tended based on additional information (Table 6). First, the
table is built vertically instead of horizontally, as is the case
in Ref. 116, thereby underscoring the various levels at which
sex development can be affected (level of chromosomal sex
vs. gonadal sex and phenotypic sex). Second, more attention
is paid to the different gonadal differentiation patterns en-
countered in a specific category of DSD, including the re-
cently described UGT pattern (not available at the time of the
consensus meeting), which is likely to be at the base of GB
formation. Third, the presence or absence of the TSPY gene
in the patients’ (gonadal) karyotype is specified. Taken to-
gether, the proposed classification system allows an imme-
diate estimation of the patient’s individual risk for germ cell
tumor development once he or she is placed in a specific
category.
A major disadvantage of this classification system is that
obtaining representative gonadal tissue (at least a bilateral
gonadal biopsy is needed) becomes essential for classifying
the patient, which makes a surgically restrictive patient care
impossible at once. Therefore, we would like to consider it as
a temporary tool to reclassify detailed patient series from the
literature and, additionally, newly diagnosed patients, in
whom a bilateral gonadectomy is, as a rule, performed at
present.
Important questions and remarks are:
• To what degree is a gonadal biopsy representative for the
whole gonad inpatientswith undervirilization syndromes
and GD? How many biopsies (at the same time and/or
with a given time interval) are necessary to generalize data
on the presence or absence of germ cells or their malignant
transformation in a biopsy specimen? How dowe exclude
the (eventually microscopical) presence of testicular or
UGT in patients with GD and predominant ovarian dif-
ferentiation based on limited biopsy material?
• The prevalence of germ cell tumors in CAIS is estimated
at 0.8%, compared with 15% in PAIS (Table 3). Prevalence
rates rise significantly after puberty. Based on our results
regarding germ cell loss in CAIS patients (28), we hypoth-
esize that even small amounts of testosterone are sufficient
to prevent germ cells from undergoing apoptosis, most
likely via indirect mechanisms mediated by the surround-
ing Sertoli cells (germ cells themselves do not have an-
drogen receptors). In this context, the following consid-
erations are relevant: Are patients with the CAIS
(provided that the diagnosis of CAIS ismade on very strict
FIG. 7. Classification of patients with DSD. The risk for
tumor development is related to the pattern and degree of
gonadal differentiation.
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criteria) at risk for germ cell tumor development at all? If
the answer is negative, it is preferable to leave their gonads
in place to allow these patients to profit from their en-
dogenous hormone production. Thus, the suggestion of
some authors (54, 117) to reclassify AIS patients into PAIS,
severe AIS, and CAIS is of relevance—the true CAIS pa-
TABLE 6. New classification system for patients with DSD
Affected level Relation to karyotype Underlying defect Gonadal differentiationpattern Testis UGT Ovary Streak
Presence of
Y/TSPYa
Gonadal sex:
Chromosomal sex (Sex
chromosome DSD)
45,X (Turner syndrome) Sex chromosome:
numerical
Complete GD (or
ovaries)b
  / / 
47,XXY (Klinefelter
syndrome)
Sex chromosome:
numerical
Testes     
45,X/46,XY and variants Sex chromosome:
numerical
Complete GD     /
Testicular dysgenesisc    / /
Ovotesticular
dysgenesisd
    /
Undifferentiated GDe /  / / /
46,XX/46,XY and
variants
Sex chromosome:
numerical
Complete GD     /
Testicular dysgenesis    / /
Ovotesticular dysgenesis     /
Undifferentiated GD /  / / /
Gonadal sex: Mutation
in sex-determining
gene
46,XY GD Mutation in sex-
determining gene
Complete GD     
Testicular dysgenesis    / 
Ovotesticular dysgenesis     
Undifferentiated GD /  / / 
Gonadal regression     
46,XX GD Mutation in sex-
determining gene
Complete GD     /
Testicular dysgenesis    / /
Ovotesticular dysgenesis     /
Undifferentiated GD /  / / /
Phenotypic sex 46,XY
(Undervirilization)
Disorders in T and DHT
biosynthesisf
Testes     
End organ resistance for
T actiong
Testes     
Testicular
unresponsiveness to
LH and hCG
Testes     
Disorders of AMH and
AMH receptor
Testes     
46,XX
(Hypervirilization)
Fetal: Disorders in
adrenal steroid
biosynthesis
Ovaries     
Fetoplacental:
aromatase deficiency
Ovaries     
Maternal androgens Ovaries     
Mutations in genes
related to ovarian
differentiation
Complete GD or ovaries   / / 
Other 46,XY Severe hypospadias,
cloacal extrophy
Testes     
46,XX Cloacal extrophy,
vaginal atresia
Ovaries     
The combined presence of testicular tissue or UGT and the TSPY gene contains an increased risk for the development of germ cell tumors.
hCG, Human chorionic gonadotropin; DHT, dihydrotestosterone; T, testosterone; AMH, anti-Mullerian hormone.
a The presence of Y/TSPY must be excluded first in the peripheral blood karyotype. If negative in the presence of testicular or UGT, it must
be excluded in gonadal tissue by fluorescence in situ hybridization or PCR.
b Normal female phenotype in the presence of bilateral streak gonads (devoid of germ cells) in a 46,XX or 46,XY individual.
c (Mostly ambiguous) phenotype resulting from the presence of one (dysgenetic) testis on one side and a streak on the other side, or of two
dysgenetic testes.
d (Mostly ambiguous) phenotype resulting from the presence of both testicular tissue consisting of seminiferous tubules, and ovarian tissue,
containing germ cells that are all enclosed in primordial and eventually growing follicles in the same individual, either in a single gonad or
in opposite gonads.
e (Mostly ambiguous) phenotype resulting from the presence of undifferentiated gonadal tissue or SC, whether or not in combination with
testicular or ovarian tissue or a streak.
f Patients with 5-reductase II deficiency should be considered separately within this group since this defect, in contrast to the other enzyme
defects, only affects the development of the male external genitalia.
g A strict subclassification of patients in groups CAIS vs. severe AIS and PAIS, based on the combination of clinical data, histology ofWolffian
duct derivatives, sequencing of the androgen receptor and androgen receptor binding studies, is essential to demonstrate the expected major
difference in tumor risk between these groups.
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tients, without pubic hair growth at puberty and without
Wolffian duct derivatives, being the only category in
which such a policy would be defendable at present. A
fourth category could include AIS phenotypic males with
infertility, in whom the prevalence of germ cell tumors is
not specifically determined at present. However, precise
information regarding the development of secondary sex-
ual characteristics (hair growth) and the presence or ab-
sence of Wolffian duct derivatives is often lacking in pub-
lished patient series and case record files. Moreover,
unless the androgen receptor mutation induces the for-
mation of a stop codon, no in vivo or in vitro test is presently
able to differentiate between these different categories.
Further research is mandatory to answer these questions.
• Very limited or no data at all exist at present regarding the
prevalence and age of occurrence of germ cell tumors in
patients with PAIS, 17-HSD deficiency, Leydig cell hy-
poplasia, and WT-1 and other gene mutations. However,
answering this question is of major importance because
these patients more and more will be reared as males,
preferably with their gonads preserved and fixed in the
scrotum. The establishment of safe follow-up protocols for
this patient population by noninvasive techniques (e.g.,
ultrasound) is mandatory. In adult males diagnosed with
CIS, it was shown that local low-dose irradiation prevents
progression toward invasiveness and allows the preser-
vation of hormonal function in most patients (118). To
what extent these data also apply to CIS lesions in the
testes of young patients with DSD remains to be examined
but is of high relevance because it possibly offers to them
an alternative to gonadectomy.
• Is the prevalence of germ cell tumors in patients with true
hermaphroditism as low as it appears to be? A low prev-
alence would indeed be expected, because their gonads
consist mainly of well-differentiated ovarian tissue, with
no risk for neoplasms, and of well-differentiated testicular
tissue, eventually displayingmaturation delay.Moreover,
60% of true hermaphrodites have a 46,XX karyotype (119).
However, to what extent the peripheral blood karyotype
in these patients corresponds to their gonadal karyotype
is actually unknown.
• In light of its suspected role in the development of germ
cell tumors, the gonadal presence of the TSPY gene and/or
protein should always be ruled out in the presence of
dysgenetic testes, SC, or true hermaphroditism, even if the
karyotype does not reveal a Y-bearing cell line.
• The diagnosis of pure GD should only be made on very
strict criteria, because the total absence of germ cells rules
out the possibility of germ cell tumors. The presence of
rare isolated germ cells in otherwise ovarian-type fibrous
stroma should always be designated as UGT and contains
a high risk for GB formation.
In view of the limited patient numbers, an intense and
multicenter collaboration is needed to answer these ques-
tions in a restricted time period. A first step to achieve this
goal was recently made during an international consensus
meeting (Chicago, IL, October 2005), where the implemen-
tation of the data presented in this article led to the proposal
of new recommendations for the management of patients
with DSDwith regard to gonadectomy (Table 7) (116). In the
future, the conclusions drawn from these guidelines may
serve as a starting point for the establishment of safe, evi-
dence-based protocols for a definitively revisedmanagement
of patients with DSD, in accordance with the possibilities
offered by modern diagnostic and surgical techniques and
with the aspirations of patient advocacy groups all over the
world.
TABLE 7. Summary of the risk of germ cell malignancy in the various forms of DSD, subdivided into high, intermediate, low, and possibly
no risk
Risk group Disorder Risk (%) Action needed No. of studies No. of patients
High GDa (Y)b intra-abd 15–35 Gonadectomyc 12 350
PAIS nonscrotal 15 Gonadectomyc 3 80
Frasier 60 Gonadectomyc 1 15
Denys-Drash (Y) 40 Gonadectomyc 1 5
Intermediate Turner (Y) 12 Gonadectomyc 11 43
17-HSD 28 Watchful waiting and possible biopsy 2 7
Low CAIS 0.8 Biopsyd and possible irrad/gonadectomy 3 120
Ovotest. DSD 3 Testicular tissue removal in case of  rearing? 3 426
Turner (Ye) 1 None 11 557
Unknownf 5-Reductase 0 Unresolved 1 3
Leydig cell hypoplasia 0 Unresolved 1 2
GD (Y)b scrotal Unknown Biopsyd and irrad? 0 0
PAIS scrotal gonad Unknown Biopsyd and irrad? 0 0
Recommended actions are indicated, as well as the number of studies and patients included in the survey. In case of PAIS, 17-HSD, and
ovotestis, the decision regarding gonadectomy is largely determined by sex of rearing. Relevant data from the recently published study by
Hannema et al. (107) are not included in this table because it is at present unclear to us to what extent patient series from this study show
overlap with patient series from a previously published study by the same group (117). Intra-abd, Intraabdominal located gonad; nonscrotal,
nonscrotally located gonad; scrotal, scrotally located gonad; irrad, local irradiation with 18 Gy; ovotest. DSD, formally ovotestis (true her-
maphrodite).
a GD (including not further specified, 46XY, 46X/46XY, mixed, partial, complete).
b GBY region positive, including the TSPY gene.
c At time of diagnosis.
d At puberty, allowing investigation of at least 30 seminiferous tubules, preferential diagnosis based on OCT3/4 immunohistochemistry.
e PCR detection of Y-chromosomal sequences (in particular the GBY region) is implicated if a marker is identified by karyotyping.
f Based on current knowledge (single study including limited number of patients, or no studies reported at all).
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